ClinicalTrials.gg
Active, not recruitingNCT06544616ReτainUpdated Nov 3, 2026

A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease

A Phase 2 interventional study of JNJ-64042056 and Placebo in Alzheimer Disease, sponsored by Janssen Pharmaceutica N.V., Belgium. Active, not recruiting at 90 sites in 9 countries. Open to participants aged 55 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Janssen Pharmaceutica N.V., Belgium (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
55
Allocation
Randomized
Ages
55 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 61 studies in Alzheimer Disease by Johnson & Johnson — 1 open to participants now, 2 under way, none of them phase 3. Alzheimer Disease · Johnson & Johnson.

Enrollment
36th of 50
55 · median 108
Started
2024
with 1 other
Phase 2
6 of 61
1 open now
Registered
61st of 61
by date

Among the 61 studies in Alzheimer Disease by Johnson & Johnson, this one is the 36th largest by enrollment of the 50 interventional ones that give a count, is one of 2 that started in 2024, is one of 6 in phase 2, and was the 61st registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

1 of the 61 studies in Alzheimer Disease by Johnson & Johnson is open now, in 10 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 55 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 61 studies in Alzheimer Disease by Johnson & Johnson, or all of them as a file.
02

Study summary

The purpose of this study is to assess whether JNJ-64042056 affects the spread and build up of tau (a protein in brain) when compared with placebo, using brain scan (tau PET) to determine results from specific areas of the brain.

03

Conditions studied

  • Alzheimer Disease

Browse trials for

04

Who can participate

Ages eligible
55 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Elevated brain tau pathology defined as Braak 3 region of interest standardized uptake value ratio (ROI SUVR) greater than (>) 1.1 (or equivalent based on emerging data) on a screening tau PET scan, reviewed centrally by a qualified reader to enrich for probability of disease progression during the study
  • Clinical Dementia Rating (CDR) global score of 0 at screening and baseline
  • (MMSE) greater than or equal to (>=) 27 (with educational adjustment) at screening
  • Able to read and write and with a minimum 5 years of formal education as reported by participant and study partner at screening
  • A participant must be of non-

Exclusion criteria

Exclusion Criteria:

  • History consistent with or known autosomal dominant AD (mutation identified in the family and/or participant)
  • Fulfills diagnostic criteria for Alzheimer's Dementia or non-Alzheimer's Dementia, including, but not limited to Frontotemporal Dementia (FTD), Diffuse Lewy Body Dementia (DLBD), Vascular Dementia (VAD), alcoholic dementia, Parkinson's dementia, Korsakov, Creutzfeldt-Jakob or other prion diseases, Posterior Cortical Atrophy
  • Diagnosis of Mild Cognitive Impairment (MCI)
  • Vitamin B12 or folate levels below the central laboratory lower limit of normal, unless the investigator determines that supplementation is not required after randomization
  • History of or current neurological disease other than preclinical AD that may make interpretation of possible new neurological signs or symptoms difficult
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
55 participants (actual)

Study arms

  • Experimental
    Arm A: JNJ-64042056

    Participants will receive intramuscular (IM) injection of JNJ-64042056 from Week 0 up to a maximum of Week 76.

    Drug: JNJ-64042056

  • Placebo comparator
    Arm B: Placebo

    Participants will receive IM injection of placebo from Week 0 up to a maximum of Week 76.

    Drug: Placebo

Interventions

  • DrugJNJ-64042056

    JNJ-64042056 will be administered intramuscularly.

  • DrugPlacebo

    Placebo will be administered intramuscularly.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Brain Tau Burden as Measured by Tau PET in Specified Regions of Interest (ROI)

    Change from baseline in brain tau burden, as measured by tau PET (including but not limited to Braak I-VI ROIs, tau naive composite ROI, Connection Rank ROI, and New Tau Composite ROI Volume) will be reported.

    Time frame: Baseline up to Week 102

Secondary outcomes

  1. Levels of IgG Titers Against Enriched Paired Helical Filaments (ePHF), p-tau and tau in Serum

    Levels of IgG titers against ePHF, p-tau peptide and tau peptide in serum will be measured.

    Time frame: Up to Week 102

  2. Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    An adverse event (AE) is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the pharmaceutical or biological agent under study. TEAEs are defined as AEs with onset or worsening on or after date of first dose of study treatment.

    Time frame: Up to Week 104

  3. Number of Participants With Reactogenicity

    Solicited AEs will be used to assess the reactogenicity of the active immunotherapy and are predefined local (at the injection site) and systemic events for which the participant is specifically questioned, and which are noted by participants in their participant diary.

    Time frame: Up to Week 78

  4. Number of Participants with Vital Signs Abnormalities

    Participants with vital signs abnormalities including temperature and blood pressure (systolic and diastolic) (supine) will be summarized over time.

    Time frame: Up to Week 102

  5. Number of Participants with Clinical Laboratory Abnormalities

    Participants with clinical laboratory abnormalities values (chemistry, hematology, urinalysis and coagulation) will be reported.

    Time frame: Up to Week 102

  6. Change from Baseline in Electrocardiogram (ECG) Values

    Change from baseline in ECG values will be reported.

    Time frame: Baseline up to Week 102

  7. Change From Baseline in Columbia-Suicidality Severity Rating Scale (C-SSRS)

    A frequency distribution of C-SSRS scores at each scheduled time point by treatment will be provided. Shifts from the baseline visit to the most severe/maximum score during the treatment period will be summarized by treatment. The maximum score assigned for each participant will also be summarized into 1 of 3 categories: no suicidal ideation or behavior (0), suicidal ideation (1 to 5), suicidal behavior (6 to 10).

    Time frame: Baseline up to Week 102

  8. Change From Baseline in Magnetic Resonance Imaging (MRI) Findings

    Change from baseline in brain MRI safety findings will be reported.

    Time frame: Baseline up to Week 102

07

Study locations

90 sites
08

References and documents

Individual participant data

Plan to share: Yes — The data sharing policy of Johnson \& Johnson Innovative Medicine is available at www.jnj.com/innovativemedicine/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu.

Data sharing details ↗ · www.jnj.com

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Dec 2026, 29 months after the start.

Of 131 industry-sponsored phase 2 interventional studies under Alzheimer Disease, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 39. This study's planned 29 months is above that.

Counting every sponsor, half of 258 studies reached it within 37 months; a quarter within 21 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 6, 2024
First posted
Aug 9, 2024
StartActual
Jul 22, 2024
Primary completionEst.
Dec 22, 2026
CompletionEst.
Jan 5, 2027
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and site details
2 updates, last Nov 3, 2026
Show all 2 updates
  1. Nov 3, 2026
    Minor edits only
    + 1 other change: verification date
  2. Sep 25, 2026
    Minor edits only
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06544616
Responsible party
Sponsor
First posted
Aug 9, 2024
Start date
Jul 22, 2024
Primary completion
Dec 22, 2026 (estimated)
Completion
Jan 5, 2027 (estimated)
Last update
Nov 3, 2026

Study contacts

Janssen Pharmaceutica N.V., Belgium Clinical trial
study director · Janssen Pharmaceutica N.V., Belgium

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion